A closed-loop synthetic gene circuit for the treatment of diet-induced obesity in mice

被引:102
作者
Roessger, Katrin [1 ]
Charpin-El-Hamri, Ghislaine [2 ]
Fussenegger, Martin [1 ,3 ]
机构
[1] Swiss Fed Inst Technol, Dept Biosyst Sci & Engn, CH-4058 Basel, Switzerland
[2] Inst Univ Technol IUTA, Dept Genie Biol, F-69622 Villeurbanne, France
[3] Univ Basel, Fac Sci, CH-4058 Basel, Switzerland
来源
NATURE COMMUNICATIONS | 2013年 / 4卷
基金
欧洲研究理事会;
关键词
ACTIVATED RECEPTOR-ALPHA; FATTY-ACIDS; PPAR-ALPHA; EXPRESSION; COREPRESSOR; CHOLESTEROL; PRAMLINTIDE; CHALLENGES; MANAGEMENT; LIGANDS;
D O I
10.1038/ncomms3825
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 ; 0710 ; 09 ;
摘要
Diet-induced obesity is a lifestyle-associated medical condition that increases the risk of developing cardiovascular disease, type 2 diabetes and certain types of cancer. Here we report the design of a closed-loop genetic circuit that constantly monitors blood fatty acid levels in the setting of diet-associated hyperlipidemia and coordinates reversible and adjustable expression of the clinically licensed appetite-suppressing peptide hormone pramlintide. Grafting of the peroxisome proliferator-activated receptor-a onto the phloretin-responsive repressor TtgR produces a synthetic intracellular lipid-sensing receptor (LSR) that reversibly induces chimeric TtgR-specific promoters in a fatty acid-adjustable manner. Mice with diet-induced obesity in which microencapsulated cells engineered for LSR-driven expression of pramlintide are implanted show significant reduction in food consumption, blood lipid levels and body weight when put on a high-fat diet. Therapeutic designer circuits that monitor levels of pathologic metabolites and link these with the tailored expression of protein pharmaceuticals may provide new opportunities for the treatment of metabolic disorders.
引用
收藏
页数:9
相关论文
共 54 条
  • [1] Building synthetic cell systems from the ground up
    Alper, Hal
    Weber, Wilfried
    [J]. CURRENT OPINION IN BIOTECHNOLOGY, 2012, 23 (05) : 641 - 643
  • [2] Biomarkers of fat and fatty acid intake
    Arab, L
    [J]. JOURNAL OF NUTRITION, 2003, 133 (03) : 925S - 932S
  • [3] Smart medication through combination of synthetic biology and cell microencapsulation
    Auslaender, Simon
    Wieland, Markus
    Fussenegger, Martin
    [J]. METABOLIC ENGINEERING, 2012, 14 (03) : 252 - 260
  • [4] Bays HE, 2011, EXPERT REV CARDIOVAS, V9, P265, DOI [10.1586/erc.10.22, 10.1586/ERC.10.22]
  • [5] Regulatory fog lifts on obesity drugs
    Bouchie, Aaron
    [J]. NATURE BIOTECHNOLOGY, 2012, 30 (09) : 810 - 811
  • [6] Drug Treatment of Obesity
    Bray G.A.
    [J]. Reviews in Endocrine and Metabolic Disorders, 2001, 2 (4) : 403 - 418
  • [7] Improvement of the monitoring and biosafety of encapsulated cells using the SFGNESTGL triple reporter system
    Catena, Raul
    Santos, Edorta
    Orive, Gorka
    Maria Hernandez, Rosa
    Luis Pedraz, Jose
    Calvo, Alfonso
    [J]. JOURNAL OF CONTROLLED RELEASE, 2010, 146 (01) : 93 - 98
  • [8] Therapeutic applications of polymeric artificial cells
    Chang, TMS
    [J]. NATURE REVIEWS DRUG DISCOVERY, 2005, 4 (03) : 221 - 235
  • [9] PPAR-α and PPAR-γ activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway
    Chinetti, G
    Lestavel, S
    Bocher, V
    Remaley, AT
    Neve, B
    Torra, IP
    Teissier, E
    Minnich, A
    Jaye, M
    Duverger, N
    Brewer, HB
    Fruchart, JC
    Clavey, V
    Staels, B
    [J]. NATURE MEDICINE, 2001, 7 (01) : 53 - 58
  • [10] Emerging roles of PPARs in inflammation and immunity
    Daynes, RA
    Jones, DC
    [J]. NATURE REVIEWS IMMUNOLOGY, 2002, 2 (10) : 748 - 759